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Background-—Antihypertensive medication use may vary by race and ethnicity. Longitudinal antihypertensive medication use
patterns are not well described in women.
Methods and Results-—Participants from the Study of Women’s Health Across the Nation (SWAN), a prospective cohort of women
(n=3302, aged 42–52), who reported a diagnosis of hypertension or antihypertensive medication use at any annual visit were
included. Antihypertensive medications were grouped by class and examined by race/ethnicity adjusting for potential confounders
in logistic regression models. A total of 1707 (51.7%) women, mean age 50.6 years, reported hypertension or used
antihypertensive medications at baseline or during follow-up (mean 9.1 years). Compared with whites, blacks were almost 3 times
as likely to receive a calcium channel blocker (odds ratio, 2.92; 95% CI, 2.24–3.82) and twice as likely to receive a thiazide diuretic
(odds ratio, 2.38; 95% CI, 1.93–2.94). Blacks also had a higher probability of reporting use of ≥2 antihypertensive medications
(odds ratio, 1.95; 95% CI, 1.55–2.45) compared with whites. Use of angiotensin-converting enzyme inhibitors/angiotensin receptor
blockers and thiazide diuretics increased over time for all racial/ethnic groups. Contrary to our hypothesis, rates of b-blocker
usage did not decrease over time.
Conclusions-—Among this large cohort of multiethnic midlife women, use of antihypertensive medications increased over time,
with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers becoming the most commonly used antihypertensive
medication, even for blacks. Thiazide diuretic utilization increased over time for all race/ethnic groups as did use of
calcium channel blockers among blacks; both patterns are in line with guideline recommendations for the management of
hypertension. ( J Am Heart Assoc. 2017;6:e004758. DOI: 10.1161/JAHA.116.004758.)
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A n estimated 76 million adults have hypertension (HTN),which translates into 1 of 3 adults.1 After age 55, women
have equal or greater prevalence of HTN compared with men.2
Life expectancy for women with HTN is on average 4.9 years
shorter than women with normal blood pressure (BP) at the age
of 50.3 The prevalence of HTN among black women in the
United States is one of the highest in the world, at more than
40%.1 Furthermore, blacks develop HTN at younger ages than
other racial/ethnic groups and are at higher risk for adverse
outcomes including stroke and renal failure.4,5
Effective management of HTN results in reduction of
cardiovascular events including stroke and heart disease.6–8
In 2002, the Antihypertensive and Lipid Lowering Treatment
to Prevent Heart Attack Trial (ALLHAT), a randomized, double-
blind, multicenter trial, compared 4 classes of antihyperten-
sive medications; angiotensin-converting enzyme inhibitors
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(ACEIs), represented by lisinopril; calcium channel blockers
(CCBs), represented by amlodipine; a-blockers, represented
by doxazosin; and thiazide diuretics (THZDs), represented by
chlorthalidone.8 The doxazosin arm was terminated early
because of increased risk for stroke, combined cardiovascular
disease (CVD), and heart failure (HF) compared with
chlorthalidone.9 Among both blacks and non-blacks,
chlorthalidone, compared with lisinopril, was associated with
significantly lower rates of HF, combined coronary heart
disease, and combined CVD. In addition, for blacks, chlorthali-
done was associated with significantly lower rates of stroke.
Compared with amlodipine, chlorthalidone was associated
with significantly lower risk for HF in both blacks and non-
blacks.8 The ALLHAT investigators recommended THZDs as
first-step therapy for HTN given equivalency between the
treatment groups for the primary outcome and the superiority
of chlorthalidone compared with amlodipine for HF, and
compared with lisinopril for combined cardiovascular disease
(CVD), stroke, and HF, as well as the lower expense of
chlorthalidone compared with lisinopril and amlodipine.8
In the following year, the Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC 7) recommended the
use of THZD diuretics as initial pharmacologic therapy for HTN
management.10 More recently, the 2014 Evidence-Based
Guidelines for the Management of High Blood Pressure in
Adults (Eighth Joint National Committee) recommended the
initiation of THZDs, or ACEIs/ARBs or CCBs, alone or in
combination for non-black patients with HTN.11 For black
patients with HTN, the writing committee recommended
THZDs or CCBs, alone or in combination.
To date, little is known about patterns of antihypertensive
medication utilization among midlife women, particularly
variations by race/ethnicity. We sought to describe patterns
of antihypertensive medication classes among women by
race/ethnicity, over time using data from the Study of
Women’s Health Across the Nation (SWAN), a prospective
cohort study of women transitioning through menopause. We
hypothesized that THZDs would increase over time, with a
greater increase around the time of ALLHAT and JNC 7
publication, and that both THZD and CCB use would increase
among blacks while ACEI/ARB use would decline. We also
hypothesized that use of b-blockers (BBs) would decline for all
women irrespective of race and ethnicity.
Methods
Study Population
SWAN is an ongoing community-based longitudinal study with
seven clinical sites. The overall aim of SWAN is to examine a
wide variety of health-related characteristics among women
transitioning through menopause. The full study design and
procedures, including recruitment and enrollment, have been
described in detail elsewhere.12,13 Between November 1995
and October 1997, 3302 women were enrolled from 7
geographically distinct sites across the United States. Sites
used various sampling frameworks and recruitment strategies
to enroll representative groups of women from the surrounding
communities. All sites enrolled non-Hispanic whites in addition
to a specific minority racial/ethnic group. For the Boston, MA;
Chicago, IL; Pittsburgh, PA; and Detroit, MI, sites, black women
were enrolled, while Chinese and Hispanic and Japanese
women were enrolled at the Oakland, CA; Hudson County, NJ;
and Los Angeles, CA, sites, respectively. Eligibility require-
ments for SWAN included age between 42 and 52 years upon
entry, menses within the 3 months prior to enrollment, and
presence of their uterus and at least one ovary at time of
enrollment. Of note, women who had their uterus and/or
ovaries removed after enrollment were not excluded but were
defined as unknown menopausal status. Women who reported
taking oral contraceptives or hormonal therapy in the prior
3 months of a screening visit were also excluded from
enrollment. Each participant read and signed an informed
consent document, and all methods used in SWAN were
approved by the institutional review boards at each study site.
For our analysis, we included women who were classified
as having HTN at any visit from the date of enrollment through
visit 12 (January 1996–April 2013). A woman was considered
to have HTN if she reported use of one or more medications
to control BP and/or reported that her healthcare provider
told her she had HTN. Women with a diagnosis of coronary
artery disease or CVD at baseline were excluded (n=72) as
they may use antihypertensive medications without a prior
diagnosis of HTN. Of the 3302 women in SWAN, 1523 women
without HTN and 72 with a diagnosis of CVD at baseline were
excluded from this analysis. A total of 1707 participants who
reported use of antihypertensives and/or reported that their
provider told them they had HTN were included in the current
analysis. Of these, 126 women were taking antihypertensive
medications but did not report HTN, and 250 women reported
HTN without taking antihypertensive medications (Figure 1).
Use of Antihypertensive Medications
The primary aim of this study was to examine antihyperten-
sive medication utilization patterns over time by medication
class for each of the racial/ethnic groups enrolled in SWAN.
Each participant was asked at each annual visit whether she
has been told by a healthcare provider that she has high BP or
a diagnosis of HTN since her last study visit. Participants also
reported on the use of all medications in the past 30 days in
the context of a detailed medication inventory and review by a
trained study interviewer at each annual visit.
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Antihypertensive drugs were grouped by class and included
the following: ACEIs/ARBs, BBs, CCBs, THZDs, a-blockers,
loop diuretics, and potassium-sparing diuretics. If a woman
reported using ≥2 antihypertensives we counted these
separately. For the multivariate models, use of ≥2 antihyper-
tensives were categorized as combination. We examined
prevalence of antihypertensive medication use over time.
SWAN did not collect data on specific doses for the majority
of visits; therefore, dose was not considered in this analysis.
Other Measures
Information on demographic characteristics was collected at
the baseline SWAN visit and included age at entry, race/
ethnicity, socioeconomic characteristics (highest education
level attained, income, occupation), calendar year, and SWAN
site. Information on medical history was assessed by self-
report at baseline and each subsequent annual visit, and
included newly diagnosed CVD, diabetes mellitus, and renal
disease. Participants were free of known CVD (prior myocar-
dial infarction, stroke, revascularization, angina) at baseline;
these outcomes were assessed at each annual visit. Income
was included in models as a categorical variable (<20K, 20 to
<50K, 50 to <100K, 100 to <150K, and 150K+). Information
on a number of additional risk factors for HTN was collected
at baseline and during follow-up, including body mass index
(kg/m2) and smoking status.
Menopausal status was defined as premenopausal, early
perimenopausal, late perimenopausal, and postmenopausal
according to predefined definitions.12,13 Premenopausal sta-
tus was defined as a menstrual period within the past
3 months with no change in regularity. Early perimenopause
was defined as a menses within the past 3 months with a
change in regularity. For these analyses, premenopausal and
early perimenopausal were combined. Late perimenopause
was defined as no menses for ≥3 months but at least one
period within the past 12 months. Postmenopause was
defined as no menses for ≥12 consecutive months with no
other reason for the amenorrhea. Menopausal status was
categorized as unknown if a woman had used hormonal
therapy, had a hysterectomy, or had bilateral salpingo-
oophorectomy prior to becoming postmenopausal. Menopau-
sal status was added to models as a time-varying covariate.
Race/ethnicity and menopausal status were examined sep-
arately as independent variables.
Statistical Analysis
We described the baseline participant characteristics in each
ethnic group using descriptive statistics (mean, median, and
range). Continuous variables were analyzed using ANOVA and
Kruskal–Wallis tests, whereas categorical variables were
analyzed using chi-square test. All variables assessed at
baseline and each annual visit were included in the models as
Figure 1. Consort diagram. CVD indicates cardiovascular disease; HTN, hypertension; SWAN, Study of
Women’s Health Across the Nation.
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time-varying covariates. After grouping the most common
antihypertensive medications by class, we examined racial
differences over time using generalized estimation equations,
starting from SWAN baseline in 1996. The autoregressive
covariance structure14 was used in each model. This structure
has homogeneous variances and correlations that decline
exponentially with distance.
Factors selected a priori for inclusion in the base models
included several covariates known to be possible correlates
of HTN: race/ethnicity (white, black, Chinese, Japanese, and
Hispanic), age, body mass index, diabetes mellitus, and
menopause transition stage. CVD events, which occurred
during follow-up, were also added to the models. Other
covariates of interest included educational level, income,
smoking status, and BP (systolic and diastolic as time-
varying covariates). Interaction terms for ethnicity and
diabetes mellitus and ethnicity and CVD were also included
in the models. Ethnicity included all race/ethnicity groups
(white, black, Chinese, Japanese, and Hispanic) when used
as an interaction term. We examined the data two ways, by
calendar year and by time relative to the final menstrual
period. We did not find any association of medication use
around final menstrual period, thus we chose to present the
data by calendar year in relation to publication of major
clinical treatment guidelines and clinical trials. Subgroup
analysis excluding the 126 women who reported use of
antihypertensive medications but did not report HTN. We
also examined use of antihypertensives by study site.
Results are expressed as odds ratios (ORs) and 95% CIs.
Since women with specific comorbidities may be pre-
scribed a particular class of antihypertensive medication, we
performed a subgroup analysis for women with diabetes
mellitus. Because of the low prevalence of vascular disease in
this cohort, medication class by stroke or transient ischemic
attack was not examined. All analyses were performed using
SAS 9.3 (SAS Institute Inc, Cary, NC).
Results
At enrollment, 46.7%, 28.3%, 8.5%, 7.8%, and 8.7% of the
3302 participants were white, black, Japanese, Chinese, and
Hispanic, respectively. A total of 1707 women reported having
been diagnosed with HTN and/or using antihypertensive
medications between January 1996 and April 2012. Charac-
teristics of these women at the visit where HTN was identified
are shown in Table 1. Among women with HTN, 42.2%, 37.9%,
5.6%, 5.6%, and 7.8% were white, black, Chinese, Japanese
and Hispanic, respectively. Mean follow-up was 9.1 years (SD
5.8 years). The mean age when HTN was first reported was
50.65.5 (SD) years. The majority (73.1%) had completed
some years of college or greater. Approximately 30% of SWAN
participants with HTN were late perimenopausal or
postmenopausal at the time of first reported diagnosis of
HTN. Mean body mass index was 31.3 kg/m2, consistent
with obesity. In terms of comorbidities, 15% of women
reported current smoking, with the highest rates for black
(21.0%) and the lowest rates for Chinese women (1.1%).
Percentage of diabetes mellitus ranged from 4.5% in Japanese
women to 13.3% in black women. Among these women, those
reporting a diagnosis of heart disease or stroke during follow-
up were low.
A total of 250 women (14.6% of all women with HTN) in the
SWAN cohort reported being diagnosed with HTN but not
taking antihypertensive medications. Black and Chinese
women were less likely to report a diagnosis of HTN without
being on pharmacotherapy as compared with white, Japanese,
or Hispanic women.
The most common classes of antihypertensive medications
used by SWAN women were THZDs (22.3%) and ACEIs/ARBs
(21.4%), followed by BBs (16.1%) and CCBs (13.4%) (Table 1).
Japanese patients reported the highest rate (38.6%) of ACEI/
ARB use, followed by Hispanics (27.8%) and blacks (26.6%).
BB use was more common among Chinese (21.1%) and
Japanese (22.3%) patients compared with the other racial/
ethnic groups. Almost one third of blacks (30.4%) were taking
a THZD compared with 19.2% of white and 18.9% of Chinese
patients. The lowest rates of THZD use were observed among
Hispanics (9.0%). The number of women who reported taking
≥2 antihypertensive medications was 12.9%. Blacks reported
the highest rates of CCB use (18.4%), followed by Hispanics
(15%). Less commonly, used antihypertensive medications
(data not shown) included non-THZD diuretics such as loop
diuretics and potassium-sparing diuretics (14.5%) and a-
blockers (0.5%).
We also examined the probability of taking a specific
antihypertensive medication class, by race/ethnicity after
adjusting for age, body mass index, menopausal status,
systolic BP, diabetes mellitus, education, and income levels
(Table 2). Among women with HTN, blacks were more likely
than whites to report using CCBs (OR, 2.92; 95% CI, 2.24–
3.82), THZDs (OR, 2.38; 95% CI, 1.93–2.94), and ≥2
antihypertensive medications (OR, 1.95; 95% CI, 1.55–2.45).
Use of ACEIs/ARBs and BBs were not statistically significantly
different between blacks and whites. Hispanic women were
more likely to report using ACEIs/ARBs (OR, 2.03; 95% CI,
1.36–3.02) and CCBs (OR, 1.81; 95% CI, 1.13–2.89),
compared with whites, while use of BBs, THZDs, and ≥2
antihypertensive medications were similar. Chinese patients
reported similar use of all antihypertensive medications
compared with whites, with the exception of CCBs, which
were used less often (OR, 0.47; 95% CI, 0.19–0.89). Among
Chinese patients, THZDs were used more often as compared
with whites (OR, 1.68; 95% CI, 1.12–2.52). No differences in
antihypertensive medication classes were observed between
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Japanese and white patients. We observed no significant
differences after further adjusting for study site (data not
shown). We also stratified by study site and found that
patterns of use were similar between sites (data not shown).
In sensitivity analyses, we observed no significant differences
when women of unknown menopausal status were removed
from the models.
Since women with diabetes mellitus may be more likely to
be prescribed ACEIs/ARBs, we examined use of antihyper-
tensive medications by race/ethnicity, comparing diabetics
with nondiabetics (Table 3). Among white, black, and
Japanese women, those with diabetes mellitus were more
likely to use ACEIs/ARBs compared with nondiabetic women
(OR, 1.70 [95% CI, 1.28–2.24] for whites, OR, 2.33 [95% CI,
1.84–2.95] for blacks, and OR 2.1 [95% CI 1.22–3.64] for
Japanese women). Black women with diabetes mellitus were
also more likely to be using ≥2 antihypertensive medications
(OR, 1.53; 95% CI, 1.12–2.0) and less likely to be taking a
THZD (OR, 0.74; 95% CI, 0.56–0.98) compared with black
nondiabetic women. We also excluded women who reported
use of antihypertensive medications but did not report having
HTN and observed no significant differences, compared with
the main analysis (Table 2), with the exception of greater CCB
use among Japanese women (OR, 1.69; 95% CI, 1.05–2.70)
(Table 4).
We next examined antihypertensive medication patterns of
use over time (Figure 2). At the beginning of data collection in
1996, use of ACEIs/ARBs, BBs, CCBs, and THZDs were
similar. By 2012, the most common antihypertensive medi-
cation class reported was ACEIs/ARBs followed by THZDs for














Age, mean (SD), y 50.6 (5.5) 50.8 (5.5) 49.7 (5.1) 52.4 (6.0) 52.2 (5.8) 50.1 (5.9) 0.0001
Education level 0.0001
High school or less 440 (25.8) 128 (17.8) 181 (28.0) 28 (29.5) 19.0 (17.0) 84 (63.2)
Some college or greater 1248 (73.1) 586 (81.4) 457 (70.6) 67 (70.5) 93 (83.0) 45 (33.8)
Menopausal status 0.02
Premenopause/early perimenopause 1064 (62.8) 434 (60.7) 441 (68.5) 47 (50.1) 61 (54.4) 81 (63.3)
Late perimenopause 89 (5.3) 39 (5.5) 30 (4.7) 7 (7.5) 6 (5.4) 7 (5.5)
Postmenopause 421 (24.8) 187 (26.1) 129 (20.1) 32 (34.0) 35 (31.3) 38 (29.7)
Menopausal status unknown* 120 (7.1) 56 (7.8) 44 (6.8) 8 (8.5) 10 (9.0) 2 (1.6)
Body mass index, mean (SD), kg/m2 31.3 (7.7) 30.8 (7.5) 33.8 (7.7) 25.2 (4.9) 24.6 (4.0) 31.6 (6.5) 0.0001
Systolic blood pressure, mean (SD), mm Hg 127 (18) 123 (15) 133 (20) 125 (15) 121 (13) 130 (13) 0.0001
Diastolic blood pressure, mean (SD), mm Hg 79 (11) 77 (6) 81 (12) 79 (11) 79 (10) 83 (9) 0.0001
Current smoking (yes or no) 263 (15.4) 97 (13.5) 136 (21) 1 (1.1) 10 (8.9) 19 (14.3) 0.0001
History of diabetes mellitus 174 (10.2) 60 (8.3) 89 (13.3) 6 (6.3) 5 (4.5) 16 (12.0) 0.006
History of CHD 12 (0.7) 3 (0.4) 7 (1.1) 2 (2.1) 0 (0.0) 0 (0.0) 0.16
History of stroke/TIA (yes or no) 12 (0.7) 7 (1.0) 1 (0.2) 2 (2.1) 1 (0.9) 1 (0.8) 0.15
Self-reported diagnosis of
HTN—not taking medication
250 (14.6) 124 (17.2) 70 (10.8) 12 (12.6) 19 (17.0) 25 (18.8) 0.007
Antihypertensive medication class
ACEI/ARB 365 (21.4) 151 (21.0) 133 (26.6) 12 (12.6) 32 (38.6) 37 (27.8) 0.02
b-Blocker 274 (16.1) 119 (16.5) 96 (14.8) 20 (21.1) 25 (22.3) 14 (10.5) 0.06
Calcium channel blocker 229 (13.4) 70 (9.7) 119 (18.4) 5 (5.3) 15 (13.4) 20 (15.0) 0.0001
Thiazide diuretic 381 (22.3) 138 (19.2) 197 (30.4) 18 (18.9) 15 (13.4) 12 (9.0) 0.0001
Use of ≥2 antihypertensive medications 220 (12.9) 77 (10.7) 107 (16.5) 4 (4.2) 18 (16.1) 14 (10.5) 0.0001
Other antihypertensive medications† 250 (14.7) 99 (39.6) 133 (53.2) 4 (1.6) 9 (3.6) 5 (2.0) 0.0001
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CHD, coronary heart disease; HTN, hypertension; TIA, transient ischemia attack.
*Menopausal status was categorized as unknown if a woman had used hormonal therapy or had a hysterectomy (with or without bilateral oophorectomy prior to their final menstrual
period).
†Other antihypertensive medications include a-blockers, nonthiazide diuretics, clonidine, hydralazine, methyldopa, minoxidil, and reserpine.
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white, black, and Japanese race/ethnic groups. The greatest
increase over time was observed for ACEIs/ARBs (20.0–
47.8%) followed by THZDs (18.8–35.7%). As the cohort aged,
greater use of ≥2 antihypertensive medications were reported
(P<0.0001). In Chinese patients, THZD use increased from
17.7% to 46% (P=0.01), and ACEI/ARB use increased from
5.9% to 33.3% (P=0.0008), while BB use remained essentially
unchanged (23.5–27%) (P=0.52). By 2012, the most common
antihypertensive medications reported by Chinese patients
were THZDs followed by ACEIs/ARBs. BB use did not decline
significantly over time among any of the groups, and
increased among the following groups: whites (P=0.0001),
blacks (P=0.0001), and Hispanics (P=0.03). Lastly, although
use of THZDs increased over time, we did not observe a
significant increased use around the time of ALLHAT or JNC 7
publication (2002–2003) or shortly thereafter (P=0.40).
Discussion
In this large, multiethnic cohort of midlife women, we
observed that use of antihypertensive medications increased
over time as participants aged. During follow-up, THZDs and
ACEI/ARB utilization increased for most racial/ethnic groups;
however, no clear uptake in THZDs was noted around the time
of publication for ALLHAT or JNC 7. Furthermore, ACEIs/ARBs
were more commonly reported compared with THZDs for
most racial/ethnic groups by 2012 and BB use did not appear
to decline over time as was expected. We also noted that the
use of CCBs was higher in black women than other groups.
The number of SWAN women who reported antihyperten-
sive medication use increased as participants aged. Ample
evidence exists demonstrating increases in HTN with age10,15;
thus, an increase in antihypertensive medications was
expected. Among participants in the Framingham Heart
Study, the probability of receiving antihypertensive medica-
tions over a lifetime was 60%. Similar rates of antihyperten-
sive use have been observed in data from the National Health
and Nutrition Examination Surveys (NHANES).16 These find-
ings show comparable rates of antihypertensive medication
reported by SWAN women.
We had expected to see a significant increase in THZD use
during, or shortly after, the years in which ALLHAT and JNC 7
were published (2002–2003). THZDs have long been recom-
mended for controlling BP, with reductions in CVD outcomes,
Table 2. Odds Ratio of Taking Antihypertensives by Medication Class and Racial/Ethnic Group
Adjusted Odds Ratio (95% CIs)
ACEIs/ARBs b-Blockers Calcium Channel Blockers Thiazide Diuretics Combination




Hispanic vs white 2.03 (1.36–3.02),
P=0.005
0.80 (0.49–1.31) 1.81 (1.13–2.89), P=0.01 0.66 (0.42–1.05) 1.31 (0.86–2.00)
Chinese vs white 0.79 (0.52–1.20) 1.20 (0.76–1.90) 0.47 (0.19–0.89), P=0.03 1.68 (1.12–2.52), P=0.01 0.83 (0.54–1.28)
Japanese vs white 1.25 (0.85–1.86) 1.22 (0.79–1.87) 1.54 (0.97–2.45) 0.98 (0.67–1.43) 1.46 (0.96–2.23)
Adjusted for age, body mass index, menopausal status, systolic blood pressure, diabetes mellitus, education, income, cardiovascular disease (CVD), ethnicity9CVD, and
ethnicity9diabetes mellitus. Combination was defined as the reported use of ≥2 antihypertensive medications by a participant. ACEIs indicates angiotensin-converting enzyme inhibitors;
ARBs, angiotensin receptor blockers.




Odds Ratio (95% CIs)
ACEIs/ARBs b-Blockers Calcium Channel Blockers Thiazide Diuretics Combination
Total 1.93 (1.47–2.53) 0.90 (0.71–1.14) 0.94 (0.66–1.35) 1.11 (0.86–1.44) 1.22 (0.93–1.60)
White 1.70 (1.28–2.24), P=0.0002 0.93 (0.73–1.18) 0.96 (0.66–1.40) 1.00 (0.78–1.31) 1.17 (0.88–1.54)
Black 2.33 (1.84–2.95), P=0.0001 1.19 (0.92–1.52) 1.02 (0.82–1.28) 0.74 (0.56–0.98), P=0.03 1.53 (1.12–2.0), P=0.001
Chinese 2.11 (0.98–4.56) 0.97 (0.54–1.70) 1.37 (0.63–3.01) 0.84 (0.62–1.12) 1.43 (0.73–2.79)
Japanese 2.10 (1.22–3.64), P=0.008 0.89 (0.63–1.26) 0.54 (0.16–1.80) 1.04 (0.34–3.20) 0.78 (0.38–1.60)
Hispanic 1.67 (0.85–3.27) 0.63 (0.26–1.52) 0.62 (0.27–1.40) 0.68 (0.29–1.58) 0.92 (0.44–1.92)
Nondiabetics are the reference group, adjusted for age, body mass index, menopausal status, systolic blood pressure, diabetes mellitus, education, income, cardiovascular disease (CVD),
ethnicity9CVD, and ethnicity9diabetes mellitus. Combination was defined as the reported use of ≥2 antihypertensive medications by a participant. ACEIs indicates angiotensin-converting
enzyme inhibitors; ARBs, angiotensin receptor blockers.
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and are low-cost agents, which can promote adherence.11,17–
19 In 2003, the JNC 7 report recommended THZDs for the
treatment of stage I HTN.10 Although we observed no specific
point of increase in THZD use during those years, an increase
in THZD and ACEI/ARB use was observed during the period
examined. ACEI/ARB use increased among all groups over
time, with the exception of Chinese women, who reported
THZDs as the most commonly used antihypertensive med-
ication class by 2012. Among the SWAN women, THZDs were
the second most commonly used antihypertensive medication
class after ACEIs/ARBs. Using data from NHANES, Gu et al16
observed diuretics to be the most commonly used antihyper-
tensive medications as of 2009–2010, of which THZDs were
the most common diuretic used. Of note, ACEIs were the
second most commonly used antihypertensive drug class.
When individual antihypertensive medications were examined,
lisinopril was the most commonly reported antihypertensive
medication used.16
In contrast, the National Disease and Therapeutic Index,
which surveyed a national sample of US physicians between
1998 and 2004, noted ACEIs to be the leading antihyperten-
sive prescribed,20 which is similar to the utilization patterns
observed in the SWAN cohort. Data from the National Disease
and Therapeutic Index did note an increase in THZD
prescriptions after publication of ALLHAT in 2002, which we
did not observe in the SWAN data.
We also expected to see a decline in the use of BBs for BP
management, given the recommendation of JNC 7. Although
there was no significant increase in BB use in general, there
was an increase among whites and blacks. In contrast to our
hypothesis, we did not observe a significant decline in use, with
the exception among Japanese patients. Prior data from
NHANES noted reductions in the use of BBs in the late 1990s
through 2002.17 However, recent data from NHANES (2009–
2010) observed an increase in BB use from 20.3% to 31.9%.16
HTN trials using BBs have not demonstrated a reduction in CVD
events in comparison to other classes of antihypertensive
medications.21,22 In the ASCOT-BPLA (Anglo-Scandinavian
Cardiac Outcome Trial-Blood Pressure Lowering) trial, adults
with HTN randomized to atenolol had higher rates of CVD
events compared with those randomized to amlodipine.22 A
meta-analysis examined use of BBs for primary HTN and also
noted no reduction in heart events with an increase in stroke.23
Consequently, current recommendations for management of
HTN do not recommend BBs as first-line agents.10,11
In the SWAN cohort, black patients were almost 3 times as
likely to report using a CCB compared with white patients.
Investigators for the MESA (Multi-Ethnic Study of Atheroscle-
rosis) trial observed that CCBs were the second most
common antihypertensive medication class used by blacks,
with ACEIs/ARBs being the most common.18,24 Among black
participants, ALLHAT investigators observed no significant
difference between the CCB amlodipine and the THZD
chlorthalidone for the primary outcome of nonfatal myocardial
infarction or coronary heart disease mortality, or secondary
outcomes including all-cause mortality, stroke, combined
coronary heart disease, or combined CVD.8 Higher rates of HF
were observed among black participants randomized to
amlodipine compared with those randomized to chlorthali-
done.25,26 In long-term follow-up of ALLHAT participants,
investigators observed that black participants had an
increased HF risk associated with amlodipine compared with
chlorthalidone.27 However, it should be noted that partici-
pants were no longer blinded to treatments during the 8 to
10 years of post-trial follow-up and may have had their
antihypertensive medication doses and class modified. Fur-
thermore, use of ACEIs/ARBs are still the most commonly
reported antihypertensive medication among blacks in SWAN.
ALLHAT observed an increased risk for stroke, combined
coronary heart disease, combined CVD, and HF in black
participants randomized to lisinopril compared with those
randomized to chlorthalidone.8 Given the ALLHAT results, and
the recent 2014 guidelines, it is surprising to see no decline in
the use of ACEIs/ARBs or CCBs among blacks.
Table 4. Odds Ratio of Taking Antihypertensives by Medication Class and Racial/Ethnic Group*
Odds Ratio (95% CIs)
ACEIs/ARBs b-Blockers Calcium Channel Blockers Thiazide Diuretics Combination




Hispanic vs white 1.86 (1.24–2.77),
P=0.003
0.84 (0.51–1.38) 1.90 (1.17–3.06), P=0.01 0.65 (0.41–1.04) 1.24 (0.81–1.89)
Chinese vs white 0.74 (0.48–1.13) 1.13 (0.70–1.85) 0.43 (0.20–0.96), P=0.04 1.70 (1.12–2.57), P=0.01 0.78 (0.51–1.21)
Japanese vs white 1.18 (0.79–1.76) 1.25 (0.79–1.96) 1.69 (1.05–2.70), P=0.03 0.96 (0.66–1.41) 1.42 (0.93–2.12)
Adjusted for age, body mass index, menopausal status, systolic blood pressure, diabetes mellitus, education, income, cardiovascular disease (CVD), ethnicity9CVD, and
ethnicity9diabetes mellitus. ACEIs indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers. Combination was defined as the reported use of ≥2
antihypertensive medications by a participant.
*Excluding women who reported antihypertensive medication use but not a diagnosis of hypertension.
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Study Strengths and Limitations
Several strengths and limitations exist in the current study.
First, data on dosage of medication was not collected for
most years of the study. This limits our ability to examine the
effective control of HTN among these women. Second,
recruitment of minorities was completed at specific sites;
therefore, differences observed in medication use patterns
may reflect geographic patterns in use as opposed to
differences by race/ethnicity. However, when we stratified
by site, patterns in medication use appear similar by race,
suggesting a lack of significant geographic variation. Last,
data collection was interrupted for one site, which included
enrollment of Hispanic women; thus, data between 2003 and
2010 are missing for Hispanics, which introduces potential for
biases when examining longitudinal trends in antihypertensive
classes for Hispanic women. We conducted a subgroup
analysis with and without these women in our models to
examine potential implications of this missing data and did
not observe differences in our results.
Figure 2. Antihypertensive medications over time by race/ethnicity. ACE indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; BB, b-blocker; CCB, calcium channel blocker; THIAZIDE, thiazide diuretic.
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Among this large cohort of multiethnic midlife women, use of
antihypertensive medications increased over time, with
ACEIs/ARBs becoming the most commonly used antihyper-
tensive medication, even for blacks. THZD use increased over
time for all race/ethnic groups as did CCB use among blacks.
Both patterns are in line with guideline recommendations for
the management of HTN.
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